289 related articles for article (PubMed ID: 17047071)
21. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
[TBL] [Abstract][Full Text] [Related]
22. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model.
Ishida T; Shiraga E; Kiwada H
J Control Release; 2009 Mar; 134(3):194-200. PubMed ID: 19095022
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model.
Chang YJ; Chang CH; Yu CY; Chang TJ; Chen LC; Chen MH; Lee TW; Ting G
Nucl Med Biol; 2010 Jan; 37(1):95-104. PubMed ID: 20122674
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with adrenal neuroblastoma.
Kawano K; Hattori Y; Iwakura H; Akamizu T; Maitani Y
Cancer Med; 2013 Jun; 2(3):286-95. PubMed ID: 23930205
[TBL] [Abstract][Full Text] [Related]
25. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
26. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
Yang Q; Tian Y; Liu S; Zeine R; Chlenski A; Salwen HR; Henkin J; Cohn SL
Cancer Res; 2007 Feb; 67(4):1716-24. PubMed ID: 17308113
[TBL] [Abstract][Full Text] [Related]
27. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors.
Chang DK; Chiu CY; Kuo SY; Lin WC; Lo A; Wang YP; Li PC; Wu HC
J Biol Chem; 2009 May; 284(19):12905-16. PubMed ID: 19276080
[TBL] [Abstract][Full Text] [Related]
28. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
30. Perfusion-guided sonopermeation of neuroblastoma: a novel strategy for monitoring and predicting liposomal doxorubicin uptake
Bellary A; Villarreal A; Eslami R; Undseth QJ; Lec B; Defnet AM; Bagrodia N; Kandel JJ; Borden MA; Shaikh S; Chopra R; Laetsch TW; Delaney LJ; Shaw CM; Eisenbrey JR; Hernandez SL; Sirsi SR
Theranostics; 2020; 10(18):8143-8161. PubMed ID: 32724463
[TBL] [Abstract][Full Text] [Related]
31. Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin.
Lundberg BB; Griffiths G; Hansen HJ
Int J Pharm; 2000 Sep; 205(1-2):101-8. PubMed ID: 11000546
[TBL] [Abstract][Full Text] [Related]
32. Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice.
Hagtvet E; Evjen TJ; Olsen DR; Fossheim SL; Nilssen EA
J Drug Target; 2011 Sep; 19(8):701-8. PubMed ID: 21524240
[TBL] [Abstract][Full Text] [Related]
33. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
34. In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP).
Atobe K; Ishida T; Ishida E; Hashimoto K; Kobayashi H; Yasuda J; Aoki T; Obata K; Kikuchi H; Akita H; Asai T; Harashima H; Oku N; Kiwada H
Biol Pharm Bull; 2007 May; 30(5):972-8. PubMed ID: 17473445
[TBL] [Abstract][Full Text] [Related]
35. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
36. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
[TBL] [Abstract][Full Text] [Related]
37. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.
Marimpietri D; Brignole C; Nico B; Pastorino F; Pezzolo A; Piccardi F; Cilli M; Di Paolo D; Pagnan G; Longo L; Perri P; Ribatti D; Ponzoni M
Clin Cancer Res; 2007 Jul; 13(13):3977-88. PubMed ID: 17606732
[TBL] [Abstract][Full Text] [Related]
38. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
39. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
Rössler J; Monnet Y; Farace F; Opolon P; Daudigeos-Dubus E; Bourredjem A; Vassal G; Geoerger B
Int J Cancer; 2011 Jun; 128(11):2748-58. PubMed ID: 20715103
[TBL] [Abstract][Full Text] [Related]
40. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
